(Q42518054)

1 November 2017

title

Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome (English)

1 reference

polycystic ovary syndrome

1 November 2017

0 references

1 reference

1 reference

1 reference

1 reference

2

Ping Wang

1 reference

1 November 2017

C J Glueck

1

1 reference

1 November 2017

Suichi Kobayashi

series ordinal

3

1 reference

1 November 2017

Harvey Phillips

series ordinal

4

1 reference

1 November 2017

Luann Sieve-Smith

series ordinal

5

1 reference

1 November 2017

language of work or name

English

0 references

publication date

1 March 2002

1 reference

1 November 2017

published in

Fertility and Sterility

1 reference

1 November 2017

volume

77

1 reference

1 November 2017

issue

3

1 reference

1 November 2017

page(s)

520-525

1 reference

Carbohydrate and lipid metabolism in pregnancy: normal compared with gestational diabetes mellitus

1 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903202-2

The epidemiology of diabetes and pregnancy in the U.S., 1988

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903202-2

Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903202-2

Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903202-2

Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903202-2

Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903202-2

Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903202-2

Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903202-2

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903202-2

Menstrual cyclicity after metformin therapy in polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903202-2

Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903202-2

Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903202-2

Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903202-2

The importance of diagnosing the polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903202-2

Obstetric outcome in women with polycystic ovarian syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903202-2

Polycystic ovaries in women with gestational diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903202-2

The prevalence of polycystic ovaries in women with a history of gestational diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903202-2

Association between polycystic ovary syndrome and glucose intolerance during pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903202-2

Endocrino-metabolic features in women with polycystic ovary syndrome during pregnancy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903202-2

Metformin in management of pregnant insulin-independent diabetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903202-2

A comparison of glyburide and insulin in women with gestational diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903202-2

A prospective analysis of the HOMA model. The Mexico City Diabetes Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903202-2

Clinical assessment of body hair growth in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903202-2

Contribution of fasting hyperinsulinemia to prediction of atherosclerotic cardiovascular disease status in 293 hyperlipidemic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903202-2

Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903202-2

Screening criteria for high-risk gestational diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903202-2

Prevalence of gestational diabetes mellitus in polycystic ovarian syndrome (PCOS) patients pregnant after ovulation induction with gonadotrophins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903202-2

Multiple metabolic defects during late pregnancy in women at high risk for type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903202-2

Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903202-2

Oral hypoglycaemic agents in 118 diabetic pregnancies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2903202-2

10.1016/S0015-0282(01)03202-2

7 January 2021

Identifiers

DOI

1 reference

1 November 2017

1 reference